Vertex Pharmaceuticals (NASDAQ: VRTX) had a fine Tuesday on the stock exchange. The biotech's shares closed the day nearly 3% ...

Vertex Pharmaceuticals is expected to report first quarter earnings on May 5, with investor focus on its two big launches and ...

It also seems to have a knack for filling those needs, as the apparent robust demand for Journavx indicates ... for investors to buy now… and Vertex Pharmaceuticals wasn’t one of them.

It also seems to have a knack for filling those needs, as the apparent robust demand for Journavx indicates ... Pfizer, and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy.

Meanwhile, for fiscal 2025, analysts expect Vertex Pharmaceuticals to report an ... and initial contributions from JOURNAVX. Furthermore, analysts' consensus view on VRTX stock is moderately ...

When the stock market is highly volatile, many investors flock to assets that offer stability but dismal growth prospects.

The biopharmaceutical industry is positioned for continued recovery, driven by recent FDA approvals and billion-dollar ...